Our analysis is based on comparing Beximco Pharmaceuticals Ltd. with the following peers – Alliance Pharma plc, BTG plc, Sinclair Pharma plc, Hikma Pharmaceuticals Plc, AstraZeneca PLC and GlaxoSmithKline plc (APH-GB, BTG-GB, SPH-GB, HIK-GB, AZN-GB and GSK-GB).
Beximco Pharmaceuticals Ltd.’s dividend yield is 2.07 percent and its dividend payout is 26.09 percent. This compares to a peer average dividend yield of 2.40 percent and a payout level of 39.36 percent. This relatively lagging dividend performance could spur some dividend action going forward – except the company’s current dividend quality score of 42 out of a possible score of 100 is only about average.
Dividend Quality Overview
- Dividend quality trend has not been consistent over the last five years. Dividends were paid during each of these years — of these 1 was high quality, 1 was medium quality and 3 were low quality.
- The ending cash balance, with a dividend coverage of 2.42x, provides a moderate cushion in case of a significant reduction of cash flows in the future.
Quadrant label definitions. Hover to know more
Over the last twelve months (prior to December 31, 2016), BXP-GB paid a low quality dividend.
The source of the company’s cash to support the dividend paid over the last twelve months is operating cash flow (coverage of 4.20x), investing cash flow (coverage of -2.78x), issuance cash flow (coverage of -0.43x) and twelve-month prior cash (coverage of 3.44x), for a total dividend coverage of 3.56x.
BXP-GB‘s issuance cash flow includes outflows from net debt repayment (coverage of -0.43x).
These coverage ratio factors imply that the firm had to dip into the beginning cash balance to pay the dividend, which suggests a low dividend quality.
|Dividend Yield (%)||0||0||0||4.15||5.85||2.07|
|Dividend Payout (%)||0.01||0.03||0||22.96||38.36||38.36|
A complete list of metrics and analysis is available on the company page.
Beximco Pharmaceuticals Ltd. is engaged in manufacturing and marketing of generic pharmaceuticals formulation products including life saving intravenous fluids, therapeutic nutrition products and active pharmaceutical ingredients. Its products include analgesics, anti-infectives, cardiovascular, intravenous fluids, central nervous system, gastrointestinal, respiratory, dermatology, muscloskeletal and ophthalmics. The company was founded in 1976 and is headquartered in Dhaka, Bangladesh.
The information presented in this report has been obtained from sources deemed to be reliable, but AnalytixInsight does not make any representation about the accuracy, completeness, or timeliness of this information. This report was produced by AnalytixInsight for informational purposes only and nothing contained herein should be construed as an offer to buy or sell or as a solicitation of an offer to buy or sell any security or derivative instrument. This report is current only as of the date that it was published and the opinions, estimates, ratings and other information may change without notice or publication. Past performance is no guarantee of future results. Prior to making an investment or other financial decision, please consult with your financial, legal and tax advisors. AnalytixInsight shall not be liable for any party’s use of this report. AnalytixInsight is not a broker-dealer and does not buy, sell, maintain a position, or make a market in any security referred to herein. One of the principal tenets for us at AnalytixInsight is that the best person to handle your finances is you. By your use of our services or by reading any our reports, you’re agreeing that you bear responsibility for your own investment research and investment decisions. You also agree that AnalytixInsight, its directors, its employees, and its agents will not be liable for any investment decision made or action taken by you and others based on news, information, opinion, or any other material generated by us and/or published through our services. For a complete copy of our disclaimer, please visit our website www.analytixinsight.com.